|
1) Dormandy J, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROactive pioglitAzone Clincal Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005; 366: 1279-89
|
|
|
|
2) Scheen A, Charbonnel B. Reduced insulin requirements and improved glycemic control with pioglitazone in insulin-treated patients with Type 2 diabetes: results from PROactive. 66th ADA
|
|
|
|
|
|
3) Wilcox R, Bousser M-G, Betterridge DJ, et al. Effects of pioglitazone in patients with Type 2 diabetes with or without previous stroke: Results from PROactive (PROactive pioglitAzone Clincal Trial In macroVascular Events 04) study. Stroke. 2007; 38: 865-73
|
|
|
|
|
|
4) Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone in recurrent myocardial infarction in 2, 445 patients with Type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) study. J Amer Coll Cardiol. 2007; 49: 1772-80
|
|
|
|
|
|
5) Wilcox R, et al. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitazone Clinical Trial In macroVasucular Events (PROactive 10). Am Heart J. 2008; 155: 12-17
|
|
|
|
|
|
6) Kawamori R, Kadowaki T, Onji M, et al. Hepatic safety profile and glycemic control of pioglitazone in more than 20, 000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan. Diabetes Res Clin Pract. 2007; 76: 229-35
|
|
|
|
|
|
7) Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-71
|
|
|
|
|
|
8) Home PD, Pocock SJ, Beck-Nielsen H, et al. for the RECORD Study Group: Rosiglitazone evaluated for cardiovascular outcomes - An interim ananlysis. N Engl J Med. 2007; 357: 28-38
|
|
|
|
|
|
9) The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication ) Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006; 368: 1096-105
|
|
|
|
|
|
10) Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-43
|
|
|
|
|
|
11) Lincoff AM, Wolski K, Nicholls J, et al. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA. 2007; 298: 1180-8
|
|
|
|
|